Understanding opportunities and challenges across all major phases of development.
MIT survey results address product and site characteristics that statistically correlate with quality performance.
When developing a strategy for using technology in biopharmaceutical manufacturing, include the interaction between automation and business systems and the roles they play in enhancing quality assurance and compliance.
This study outlines methods for an alternative protein-polishing process for challenging proteins.
Scaling up stem-cell cultures requires careful consideration of the bioreactor design.
This article discusses the evaluation of a novel single-use fluidized bed centrifuge for harvesting of antibodies.
MAb polishing using salt tolerant interaction membrane chromatography.
This article describes best practices for implementing a single-use process train at a bioproduction facility.
Preparation of biological samples for chromatographic analyses.
The authors review the various analytical methods that can enable use of PAT.
Current expectations in bioprocessing and a framework for using NMR to enhance a QbD approach.
MIT survey results address product and site characteristics that statistically correlate with quality performance.
Members from an ASQ working group provide analytical methods to enable PAT.
A step-wise process is used to characterize glycans and understand the functioning of a molecule for biosimilar development.
The census reveals the state of the population of India's health and the potential for growth in the healthcare market.
A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.
Working together affords many unseen opportunities for pharmaceutical innovation.
Demonstration of large-scale stem-cell scale-up.
The authors present approaches used to reduce reconstitution time of a lyophilized high-concentration protein drug product.
by Joseph Noferi, Edward R. Arling, Ralph L. Dillon, and Mikael Blomqvist, Pharmacia An FDA Warning Letter can be a business disaster. This case study tracks a company from receipt of an FD 483 ? that did not find contamination, but only the potential for contamination ? to 18 months later when the facility received a clean bill of health. What it did to get there ? and what it learned ? may keep your site from losing its operating freedom.
The authors present scale-up from a 5-L fermentor to a 50-L pilot-scale using the criterion of constant power consumption per unit liquid volume.
MIT survey results address product and site characteristics that statistically correlate with quality performance.